Clinical Trial Update: A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial investigating 4 weeks of dosing with XEN-D0501 for blood glucose reduction in adults with type 2 diabetes; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• XEN-D0501

Snippet

Sponsor: Pila Pharma | Conditions: Efficacy, Safety | Phase 2 | Status: COMPLETED